文献速递血管炎其他结缔组织病

美泊利单抗治疗嗜酸性肉芽肿性多血管炎:欧洲多中心观察性研究

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
PubMed 文献 · Arthritis Rheumatol · 2021-12-30

两剂量均显著降低BVAS评分、泼尼松剂量和嗜酸性粒细胞计数,完全缓解率随时间增加且两剂量可比,安全性可接受。

要点

  • 美泊利单抗100 mg和300 mg每4周均可有效治疗EGPA。
  • 两剂量在完全缓解率及BVAS、泼尼松剂量、嗜酸性粒细胞下降方面无显著差异。
  • 哮喘急性发作常见(40.4%),多数不良事件为非严重性。

核心结论

  • 美泊利单抗100 mg每4周与300 mg每4周对EGPA均有效,两剂量应在对照试验中比较。

主要发现

  • 美泊利单抗从3个月至24个月显著降低BVAS评分、泼尼松剂量和嗜酸性粒细胞计数,两剂量间无显著差异。
  • 44例(21.7%)发生不良事件,其中38/44为非严重性不良事件。

关键数值与推荐

  • 完全缓解定义为无疾病活动(BVAS=0)且泼尼松或泼尼松龙剂量(或等效)≤4 mg/天。

临床怎么用

  • 美泊利单抗100 mg每4周或300 mg每4周可用于EGPA治疗,需关注哮喘和耳鼻喉急性发作。

局限性

  • 为观察性研究,非随机对照,两剂量比较需在对照试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. METHODS: We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015-2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ≤4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. RESULTS: Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty-five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty-two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). CONCLUSION: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bettiol A, Urban ML, Dagna L, et al. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis Rheumatol. 2021. PMID: 34347947. doi:10.1002/art.41943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。